Currently, the only approved treatment for MASH on the market is the thyroid hormone receptor β agonist resmetirom (Rezdiffra ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

I’ve no history of nosebleeds, but over the past five weeks, I’ve had five. The first three times, the bleeding stopped after ...

Any thoughts on milk thistle supplements in fatty liver disease that was diagnosed by an ultrasound due to elevated AST and ...

Their medication, Rezdiffra (resmetirom), is the first FDA-approved treatment for MASH with moderate to advanced fibrosis and is currently undergoing a Phase 3 trial for compensated MASH cirrhosis.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

A new medicine, resmetirom (Rezdiffra), is poised to make a dramatic change in the treatment for people with fibrosis. Because milk thistle is quite safe at recommended doses, I doubt there is any ...

Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication ...

New technology and drugs are transforming how doctors detect and treat silent liver disease MASLD before it leads to liver ...